文献速递神经肿瘤

氨基酸PET对新诊断IDH突变胶质瘤的预后分层

Prognostic stratification of newly diagnosed IDH-mutant gliomas by [18F]fluoroethyltyrosine and [11C]methionine PET: A retrospective, bicentric cohort study.
PubMed 文献 · Neuro Oncol · 2025-01-01

这项双中心回顾性研究纳入457例IDH突变胶质瘤患者,分析放疗或系统治疗前[18F]FET或[11C]MET PET参数与至下次干预时间(TTNI)和总生存(OS)的关系。星形细胞瘤中TBRmax、TBRmean和PET体积与TTNI及OS相关,少突胶质细胞瘤中PET体积与TTNI相关。

要点

  • 星形细胞瘤PET可测量病变量与更短TTNI相关(中位46.0 vs 67.9个月,P=.004)。
  • 星形细胞瘤TTNI与TBRmax(HR 1.48)和TBRmean(HR 1.93)独立相关。
  • 少突胶质细胞瘤PET体积每增10 ml与TTNI相关(HR 1.18)。

核心结论

  • 在新诊断IDH突变胶质瘤中,氨基酸PET参数与预后结局相关。
  • 未来临床试验应纳入PET成像以定义基于影像的预后特征。

研究设计与样本

  • 双中心回顾性队列研究,纳入457例IDH突变胶质瘤患者。
  • 患者均在放疗或系统治疗前接受[18F]FET或[11C]MET PET检查。

主要发现

  • 251例(54.9%)为星形细胞瘤,206例(45.1%)为少突胶质细胞瘤。
  • 星形细胞瘤切除前PET按RANO 1.0可测量病变量者TTNI更短(中位46.0 vs 67.9个月;P=.004)。
  • 星形细胞瘤单因素分析示TTNI与TBRmax、TBRmean和PET体积相关,少突胶质细胞瘤TTNI与PET体积相关。
  • 星形细胞瘤多因素分析示TTNI与TBRmax(HR 1.48 [95%CI: 1.09-2.01])和TBRmean(HR 1.93 [95%CI: 1.14-3.27])相关。
  • 少突胶质细胞瘤多因素分析示PET体积每增加10 ml与TTNI相关(HR 1.18 [95%CI: 1.03-1.36])。

关键数值与推荐

  • 星形细胞瘤单因素分析示OS与TBRmax(HR 1.40 [95%CI: 1.13-1.74])、TBRmean(HR 1.97 [95%CI: 1.21-3.22])和PET体积(HR 1.23 [95%CI: 1.10-1.37])相关。
  • 考虑PET时间点的进一步分析结果一致。

临床怎么用

  • 氨基酸PET参数可用于IDH突变胶质瘤的预后分层辅助决策。
  • 星形细胞瘤中TBRmax、TBRmean和PET体积升高提示TTNI和OS风险增加。
  • 少突胶质细胞瘤中PET体积增大提示TTNI缩短。

局限性

  • 本研究为回顾性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Improved prognostic stratification, including imaging-based parameters, is needed to guide treatment decisions in IDH-mutant glioma. METHODS: In this bicentric retrospective study, 457 patients with IDH-mutant glioma and [18F]fluoroethyltyrosine or [11C]methionine positron emission tomography (PET) prior to radiotherapy or systemic treatment were included. Associations of maximum and mean tumor-to-background ratios (TBRmax/TBRmean) and PET-positive volume (PET volume) with time to next intervention (TTNI) and overall survival (OS) were analyzed. RESULTS: Overall, 251 (54.9%) patients with astrocytoma and 206 (45.1%) with oligodendroglioma were included. In patients with astrocytoma who underwent PET before resection, measurable disease according to PET RANO 1.0 criteria was associated with shorter TTNI compared to no/non-measurable disease (median 46.0 vs. 67.9 months; P = .004). Univariable analysis showed an association of TTNI with TBRmax, TBRmean, and PET volume in astrocytoma and PET volume in oligodendroglioma. Multivariable analyses including age, WHO grade, extent of resection, postoperative treatment, and magnetic resonance imaging (MRI)-based tumor extent indicated an association of TTNI with TBRmax (HR 1.48 [95%CI: 1.09-2.01]) and TBRmean (HR 1.93 [95%CI: 1.14-3.27]) in astrocytoma and PET volume (HR [10 ml increase]: 1.18 [95%CI: 1.03-1.36]) in oligodendroglioma. In astrocytoma, also OS was related to TBRmax (HR: 1.40 [95%CI: 1.13-1.74]), TBRmean (HR: 1.97 [95%CI: 1.21-3.22]), and PET volume (HR: 1.23 [95%CI: 1.10-1.37]) in univariable analysis. Further analyses considering timepoint of PET showed consistent results. CONCLUSIONS: In this retrospective study, amino acid PET parameters were associated with outcome in newly diagnosed IDH-mutant glioma. Future clinical trials should include PET imaging to define imaging-based prognostic signatures.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Mair MJ, Werner JM, Weller J, et al. Prognostic stratification of newly diagnosed IDH-mutant gliomas by [18F]fluoroethyltyrosine and [11C]methionine PET: A retrospective, bicentric cohort study. Neuro Oncol. 2025. PMID: 40856188. doi:10.1093/neuonc/noaf196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。